<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Modigraf" /><meta name="IX" content="Modigraf" /><title>Modigraf®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="208985.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="208985.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=208985.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4777.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="4782.htm">8.2.2 Corticosteroids and other immunosuppressants</a> &gt; <a href="27585.htm">TACROLIMUS</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="106034.htm" title="Previous: SIROLIMUS">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="208986.htm" title="Next: 8.2.3 Anti-lymphocyte monoclonal antibodies">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301040.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus (Topical)</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Skin and Mucous Membrane Agents 84:00 &gt; Skin and Mucous Membrane Agents, Miscellaneous 84:92</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a395035.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Immunosuppressive Agents 92:44</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/4992-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Tacrolimus</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: T &gt; Interactions of Tacrolimus</p></div></li></ul><ul><li><h3>British National Formulary (6)</h3></li><li><a href="4782.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.2 Corticosteroids and other immunosuppressants</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="27585.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">TACROLIMUS</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.2 Corticosteroids and other immunosuppressants</p></div></li><li><a href="106473.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">13.5.3 Drugs affecting the immune response</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 13 Skin &gt; 13.5 Preparations for eczema and psoriasis</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22tacrolimus%22%22tacrolimus%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (6)</a></li></ul><ul><li><h3>BNF for Children (8)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/100044.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Immunosuppressant therapy</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4782.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.2 Corticosteroids and other immunosuppressants</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/27585.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">TACROLIMUS</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.2 Corticosteroids and other immunosuppressants</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22tacrolimus%22%22tacrolimus%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (8)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1557.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a595003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0019s0008.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/t01-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; T</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/4992-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Immunosuppressants &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09025.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; T &gt; TA</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D124.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Tacrolimus</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Drug Administration via Enteral Feeding Tubes</h3></li><li><a href="http://www.medicinescomplete.com/mc/tubes/2010/c352.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tacrolimus</a><div class="breadcrumb"><p><strong>Drug Administration via Enteral Feeding Tubes</strong> &gt; Handbook of Drug Administration via Enteral Feeding Tubes &gt; Monographs &gt; T</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_27585">TACROLIMUS</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i730.htm" title="Go to appendix 1">Tacrolimus</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">prophylaxis of organ rejection in liver,
kidney, and heart allograft recipients and allograft rejection resistant
to conventional immunosuppressive regimens, see also notes above;
moderate to severe atopic eczema (section 13.5.3)</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">monitor blood pressure, ECG (<b>important:</b> see Cardiomyopathy below), fasting blood-glucose
concentration, haematological and neurological (including visual)
parameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration
(especially during episodes of diarrhoea)—consult local treatment
protocol for details; QT-interval prolongation; neurotoxicity; increased
risk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight; <b>interactions:</b> Appendix 1 (<span>tacrolimus</span>)</p><div class="cAV"><h3>Driving</h3> <p class="cAX">May affect performance of
skilled tasks (e.g. driving)</p></div></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">hypersensitivity to macrolides; avoid concurrent administration with <span>ciclosporin</span> (care if patient has previously received <span>ciclosporin</span>)</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">dose reduction may be necessary in severe impairment</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">exclude before treatment; avoid unless potential
benefit outweighs risk—risk of premature delivery, intra-uterine growth
restriction, and hyperkalaemia; toxicity in <i>animal</i> studies</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">avoid—present in breast milk</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">nausea, vomiting, diarrhoea, constipation, dyspepsia,
flatulence, bloating, weight changes, anorexia, gastro-intestinal
inflammation, ulceration, and perforation, hepatic dysfunction, jaundice,
cholestasis, ascites, bile-duct abnormalities, oedema, tachycardia,
hypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea,
pleural effusion, parenchymal lung disorders, sleep disturbances,
tremor, headache, peripheral neuropathy, mood changes, depression,
confusion, anxiety, psychosis, seizures, paraesthesia, dizziness,
renal impairment, renal failure, renal tubular necrosis, urinary abnormalities,
hyperglycaemia, electrolyte disturbances (including hyperkalaemia,
hypokalaemia, and hyperuricaemia), blood disorders (including anaemia,
leucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle
cramp, visual disturbances, photophobia, tinnitus, impaired hearing,
alopecia, sweating, acne; <i>less commonly</i> paralytic
ileus, gastro-intestinal reflux disease, peritonitis, pancreatitis,
heart failure, arrhythmia, cardiac arrest, cerebrovascular accident,
cardiomyopathy (<b>important</b>: see Cardiomyopathy below),
palpitation, respiratory failure, coma, speech disorder, amnesia,
paralysis, influenza-like symptoms, encephalopathy, coagulation disorders,
photosensitivity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia,
dermatitis; <i>rarely</i> pericardial effusion, respiratory
distress syndrome, posterior reversible encephalopathy syndrome, dehydration,
thrombotic thrombocytopenic purpura, blindness, toxic epidermal necrolysis,
hirsutism; <i>very rarely</i> myasthenia, haemorrhagic cystitis,
Stevens-Johnson syndrome</p><div class="cAV"><h3>Cardiomyopathy</h3> <p class="cAX">Cardiomyopathy has been reported
in children. Patients should be monitored by echocardiography for
hypertrophic changes—consider dose reduction or discontinuation if
these occur</p></div></div><div class="cAF"><h2>Dose</h2> <p class="cR">See under preparations</p></div><div id="_201712"><div class="cN"><h3 class="cBP">Important</h3><p><span class="cZ">Adoport</span>®, <span class="cZ">Prograf</span>®, <span class="cZ">Modigraf</span>®, <span class="cZ">Tacni</span>®, <span class="cZ">Vivadex</span>®, and <span class="cZ">Advagraf</span>® (tacrolimus): serious medication
errors</p><p>There are 3 different oral formulations of tacrolimus:</p><ul class="cBF"><li><p class="cQ"><span class="cZ">Adoport</span>®, <span class="cZ">Prograf</span>®, <span class="cZ">Tacni</span>®, and <span class="cZ">Vivadex</span>® are
immediate-release capsules that are taken twice daily, once in the
morning and once in the evening;</p></li><li><p class="cQ"><span class="cZ">Modigraf</span>® granules are used to prepare
an immediate-release oral suspension which is taken twice daily, once
in the morning and once in the evening;</p></li><li><p class="cQ"><span class="cZ">Advagraf</span>® is a prolonged-release capsule
that is taken once daily in the morning.</p></li></ul><p>Switching between different oral formulations of tacrolimus
requires careful therapeutic monitoring.</p><p>Changes to oral tacrolimus therapy should be made only under
the close supervision of a transplant specialist.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="213817.htm#_213817" title="Adoport®">Adoport®</a></li><li class="jN" id="_208985" style="margin: 0 0 0 20px;"><h1 class="title">Modigraf®<span> (<a href="appendix-112803-A.htm#m697">Astellas</a>)</span> <a href="204285.htm" title="Report adverse reaction(s)"><img class="cK" src="images/blacktri_s.png" alt="Black triangle" /></a> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Granules</span>, <span>tacrolimus</span> (as monohydrate), 200 micrograms, net price 50-sachet pack = £71.30;
1 mg, 50-sachet pack = £356.65. 
    Label:
    13, 23, counselling, driving<div class="cAQ"><div class="cAV"><h3>Note</h3> <p class="cAX">Tacrolimus is incompatible with PVC</p></div><div class="cAF"><h2>Dose</h2> <p class="cAF">liver transplantation, starting 12 hours after transplantation, <span class="cU">by mouth</span>, 100–200 micrograms/kg daily in 2 divided doses; <span class="cAK">child</span> 300 micrograms/kg daily in 2 divided doses</p><p>Renal transplantation, starting within 24 hours of transplantation, <span class="cU">by mouth</span>, 200–300 micrograms/kg daily in 2 divided doses; <span class="cAK">child</span> 300 micrograms/kg daily in 2 divided doses</p><p>Heart transplantation with antibody induction (starting within
5 days of transplantation) or without antibody induction (starting
within 12 hours of transplantation), <span class="cU">by mouth</span>, 75 micrograms/kg
daily in 2 divided doses; <span class="cAK">child</span>, with
antibody induction (starting within 5 days of transplantation), 100–300 micrograms/kg
daily in 2 divided doses; without antibody induction (starting within
12 hours of transplantation), 300 micrograms/kg daily in 2 divided
doses as soon as clinically possible (8–12 hours after discontinuing
intravenous infusion)</p><p>Maintenance treatment, dose adjusted according to response and
whole blood concentration</p><p>Rejection therapy, seek specialist advice</p></div><div class="cAV"><h3>Note</h3> <p class="cAX">The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (November 2010) that tacrolimus granules for oral suspension
(<span class="cZ">Modigraf</span>®) are accepted for restricted use within
NHS Scotland in patients for whom tacrolimus is an appropriate choice
of immunosuppressive therapy and where small changes (less than 500 micrograms)
in dosing increments are required (such as, in paediatric patients)
or seriously ill patients who are unable to swallow tacrolimus capsules.</p></div></div></div></li><li><a href="27587.htm#_27587" title="Prograf®">Prograf®</a></li><li><a href="217767.htm#_217767" title="Tacni®">Tacni®</a></li><li><a href="215609.htm#_215609" title="Vivadex®">Vivadex®</a></li><li id="_200014__200014"><a href="200014.htm#_200014" title="Modified release">Modified release</a><ul style="display: none"><li><a href="200015.htm#_200015" title="Advagraf®">Advagraf®</a></li></ul></li><li><a href="202852.htm#_202852" title="Tacrolimus formulations [unlicensed]">Tacrolimus formulations [unlicensed]</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="106034.htm">Previous: SIROLIMUS</a> | <a class="top" href="208985.htm#">Top</a> | <a accesskey="]" href="208986.htm">Next: 8.2.3 Anti-lymphocyte monoclonal antibodies</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>